New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy

New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy

The treatment of metastatic prostate cancer has evolved over the decades focusing on manipulation of the androgen receptor pathway with or without chemotherapy. Despite new drugs discovered with incrementing survival benefits, the disease continues to be fatal after development of castration resista...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pedro Henrique Isaacsson Velho, Katia Regina Marchetti, Gabriel Passos Souza
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações Ltda. 2018-04-01
Series:	Brazilian Journal of Oncology
Subjects:	Prostatic Neoplasm Castration-Resistant Testosterone Prostate-Specific Antigen Neoplasias da Próstata Resistente à Castração Testosterona Antígeno Prostático Específico
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20180003
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cambios en el valor del antígeno prostático específico en pacientes con COVID-19
by: Yildiray Yildiz, et al.
Published: (2025-07-01)

Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
by: Rodrigo Bovolin de Medeiros, et al.
Published: (2019-01-01)

Biomarcadores en el diagnóstico temprano y tratamiento de cáncer
by: Melissa Camacho-Sánchez, et al.
Published: (2023-03-01)

Evaluación del cáncer de próstata con PET/CT PSMA: hallazgos imagenológicos y claves para la correcta interpretación
by: Aarón H. Pérez-Segovia, et al.
Published: (2025-04-01)

Prostate-specific Antigen as a Predictor for the Diagnosis of Prostate Adenocarcinoma
by: Wilfredo Valiente Morejón, et al.
Published: (2015-11-01)

Densidad de antígeno prostático y resonancia multiplanar como predictores en diagnóstico de cáncer
by: Lizbeidy Vinaja, et al.
Published: (2025-04-01)

Revisión sistemática de las recomendaciones GRADE para la estadificación del cáncer de próstata
by: Dayana Sáenz, et al.
Published: (2025-05-01)

Score genético predice agresividad del cáncer de próstata.
by: Pablo Rojas, et al.
Published: (2018-07-01)

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01)

Treatment of Advanced Prostate Cancer: Where Are We in 2019?
by: Fernando Sabino Marques Monteiro, et al.
Published: (2019-01-01)

Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting
by: Jayachandran Perumal Kalaiyarasi, et al.
Published: (2019-01-01)

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade
by: Vojinov Saša, et al.
Published: (2011-01-01)

Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
by: Fangming Wang, et al.
Published: (2025-05-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005–2024)
by: Jiexiang Zhang, et al.
Published: (2025-07-01)

Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer
by: Maria Malvina Tsamouri, et al.
Published: (2025-08-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients
by: Gede Wirya Kusuma Duarsa, et al.
Published: (2021-07-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Screening and validation of key genes involved in castration-resistant prostate cancer based on transcriptomics sequencing
by: Guangquan Tong, et al.
Published: (2025-07-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer
by: Haq Dad, et al.
Published: (2025-01-01)

Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
by: Ze Wang, et al.
Published: (2025-08-01)

The correlation between the expression of androgen receptor splice variant-7 (AR-V7) protein with the time of occurrence of castration-resistant prostate cancer and overall survival in prostate cancer in Indonesian population
by: Indrawarman Soerohardjo, et al.
Published: (2025-02-01)

Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
by: Sayeh Fattahi, et al.
Published: (2025-08-01)

The impact of exercise on prostate-specific antigen and testosterone in prostate cancer: a systematic review and meta-analysis
by: Fuxun Zhang, et al.
Published: (2025-12-01)

Role of exosomes in castration-resistant prostate cancer
by: Yuan Cao, et al.
Published: (2025-05-01)

Prognostic factors for patients treated with abiraterone
by: Cecília M Alvim, et al.
Published: (2020-02-01)

Long-term ultrasonographic changes of the canine prostate gland after castration
by: Stefano Spada, et al.
Published: (2025-01-01)

Amphibian newts as experimental models for studying weight gain after castration
by: Mai Takehara, et al.
Published: (2024-02-01)

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
by: Sandra Doveson, et al.
Published: (2025-03-01)

Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer
by: Yuqi Guo, et al.
Published: (2025-03-01)

KAT5 promotes tumor growth in androgen-independent prostate cancer by facilitating aerobic glycolysis
by: Wei He, et al.
Published: (2025-08-01)

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)